Biosimilar cost savings yet to materialise, says healthcare organisation

Although the biosimilar market in the US is still early in development, US payers believe that the expected cost savings offer ed by biosimilar products have yet to materialise.

This is according to RG+A’s Health Payer Council, an online community of managed care pharmacy and medical directors.

The organisation said that biosimilars are likely to continue to face pricing pressure from innovator counterparts, and competition from other biosimilar products.

Enid McDonough, RG+A’s vice president for market access, said: “All payers are considering new, harder-edged strategies when debating coverage and management for biosimilar agents.”

He added: “This is particularly true of PBMs, which are drawing a hard line in the sand when determining coverage.”